Clinical trials: Migraine, Acute
Migraine Disorders
Reliability of Rimegepant or Triptans for the Acute Treatment of Migraine
This protocol describes the analysis of the Adelphi Real World (ARW) Migraine Disease Specific Programme(TM) 2022, a cross-sectional study which used both physician and patient surveys to assess the perception of the acute…
- Trial name
- Adelphi DSP (NCT06412965)
- Where
- United States
- Volunteers
- 528 people
- Sponsor
- Pfizer
Migraine, Head Pain
A Study Comparing the Effectiveness and Safety of ULTRACET® (Tramadol HCl/Acetaminophen) Versus Placebo for the Treatment of Acute Pain From a Migraine Headache
The purpose of this study is to evaluate the effectiveness and safety of tramadol HCl/acetaminophen as a pain medication compared with placebo in the treatment of acute pain from a migraine headache.
- Conditions
- Migraine, Head Pain, Headache
- Trial name
- NCT00297375
- Testing
- tramadol HCl/acetaminophen
- Volunteers
- 375 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Ischemic Stroke, Migraine
Sensitivity to Acute Cerebral Ischemia in Migrainers
Sensitivity to Acute Middle cerebral or intracranial Carotid artery Occlusion in MIGrainers (SMCO-MIG) is a prospective multi-center study to determine if migraine induces a faster infarct growth as assessed by initial multimodal…
- Conditions
- Ischemic Stroke, Migraine, Migraine With Aura
- Trial name
- SAMCO-MIG (NCT03301441)
- Testing
- questionnaire ef-ID Migraine
- Where
- France
- Volunteers
- 605 people
- Sponsor
- University Hospital, Montpellier
Migraine Headache
A Study on the Usability of the Needle-free Intraject® System in Adult Patients During Acute Migraine Attack
Intraject is a needle-free, single use, disposable, subcutaneous delivery system pre-filled with 6mg Sumatriptan to be used by patients to treat acute migraine treatment.
- Trial name
- NCT00530517
- Testing
- Intraject Sumatriptan
- Where
- 4 sites in United States
- Volunteers
- 54 people
- Sponsor
- Zogenix, Inc.
Migraine
Randomized Trial in Adult Participants With Acute Migraines
The purpose of this study is to test the safety and efficacy of BHV-3500 (zavegepant) versus placebo in the acute treatment of moderate or severe migraine.
- Trial name
- NCT04571060
- Testing
- Zavegepant
- Where
- 94 sites in United States
- Volunteers
- 1,978 people
- Sponsor
- Pfizer
Migraine, Headache
Efficacy and Safety of a Fixed-dose Combination of Naratriptan and Naproxen in Acute Treatment of Migraine.
The purpose of this study is to determine whether a fixed-dose combination of naratriptan 2,5 mg + naproxen 500 mg is effective and safe compared each monotherapy for the acute treatment of migraine.
- Trial name
- Copérnico (NCT01726920)
- Testing
- naratriptan + naproxen, naratriptan, naproxen
- Sponsor
- Ache Laboratorios Farmaceuticos S.A.
Migraine Headaches
Study to Determine the Efficacy and Safety of ELS-M11 in Acute Migraine
This is a Phase 1/ Phase 2, 12-week, multi-center, randomized, double-blind, cross-over, placebo-controlled study to evaluate the efficacy and safety of ELS-M11 compared to placebo in 50 male and female subjects, aged 18 to 65…
- Trial name
- NCT02057315
- Testing
- ELS-M11
- Where
- 2 sites in United States
- Volunteers
- 48 people
- Sponsor
- Achelios Therapeutics
Episodic Migraine
The Effects of Expectation and Knowledge on Rizatriptan and Placebo Treatment of Acute Migraine Headache
Evidence-based medicine depends on distinguishing between pharmacological effects and placebo effects in randomized controlled trials (RCT).
- Trial name
- NCT00719134
- Testing
- Maxalt
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- Beth Israel Deaconess Medical Center
Migraine Headache
IM Ketorolac vs Cambia for the Acute Treatment of Severe Migraine
This research will be conducted to see if the oral drug Cambia is as effective in relieving severe migraine headaches as the injectable drug ketorolac.
- Trial name
- NCT02664116
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Scripps Health
Migraine With or Without Aura
Eletriptan for the Treatment of Migraine in Patients With Previous Poor Response or Tolerance to Oral Sumatriptan
To determine the tolerability and efficacy of eletriptan in patients who had discontinued oral sumatriptan due to lack of efficacy or intolerable adverse events (AEs) during previous clinical treatment (not a controlled trial).
- Trial name
- NCT01989936
- Testing
- Eletriptan 40 mg, Eletriptan 80 mg
- Where
- 43 sites in Denmark, Finland and 3 more
- Volunteers
- 446 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Migraine in Adolescence
Real-world Data Analysis of REN Treatment in Adolescence With Migraine
This is a Post-marketing study investigating the safety and efficacy of the REN device (Nerivio by Theranica, Israel) in adolescents with migraine.
- Trial name
- NCT05443659
- Testing
- Nerivio
- Where
- 2 sites in United States, Israel
- Volunteers
- 1,629 people
- Sponsor
- Theranica
Migraine, With or Without Aura
Open Label Safety Study in Acute Treatment of Migraine
The purpose of this study is to evaluate safety and tolerability of BHV-3000 (rimegepant).
- Trial name
- NCT03266588
- Testing
- Rimegepant
- Where
- 98 sites in United States
- Volunteers
- 3,019 people
- Sponsor
- Pfizer
Migraine, Headache
Efficacy and Safety of a Fixed-dose Combination of Naratriptan and Naproxen in Acute Treatment of Migraine
The purpose of this study is to determine whether a fixed-dose combination of naratriptan + naproxen is effective compared each monotherapy for the acute treatment of migraine.
- Trial name
- Atenéia (NCT01390324)
- Testing
- Fixed-dose combination of naratriptan+naproxen, Naratriptan, Naproxen
- Sponsor
- Ache Laboratorios Farmaceuticos S.A.
Migraine Headaches
Acute Migraine Treatment in the ED With Gepants
This study evaluates the effectiveness of rimegepant 75 mg orally disintegrating tablet (ODT) single-dose or zavegepant 10 mg nasal spray single-dose as acute migraine treatments during Emergency Department (ED) encounters.
- Trial name
- NCT06985342
- Testing
- Rimegepant, Zavegepant
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Migraine
Greater Occipital Nerve Block Versus Metoclopramide
We are comparing a type of nerve block called greater occipital nerve block versus standard therapy among patients who present to an emergency department for acute migraine. This is a randomized, double-blind, double dummy study.
- Trial name
- NCT03269435
- Testing
- Greater occipital nerve block with bupivacaine, Metoclopramide
- Where
- United States
- Volunteers
- 99 people
- Sponsor
- Montefiore Medical Center
Episodic Migraine, Migraine With Aura
Mi-Helper Transnasal Cooling for Acute Treatment of Migraine
This is a prospective, double-blind, sham-controlled, randomized clinical trial . This study aims to assess the efficacy, safety, tolerability, and the optimal dose of the Mi-Helper transnasal cooling device for acute treatment…
- Conditions
- Episodic Migraine, Migraine With Aura, Migraine Without Aura, Migraine
- Trial name
- NCT06051604
- Testing
- Mi-Helper
- Where
- United States
- Volunteers
- 172 people
- Sponsor
- CoolTech LLC
Acute Migraine
Migraine Treatment With Nerivio Migra Neurostimulation Device
This is a prospective, randomized, double-blind, sham controlled multi-center trial. Ratio between treatment and control groups will be 1:1, stratified by center and use of preventive medications.
- Trial name
- NCT03076515
- Testing
- Nerivio Migra neurostimulation
- Where
- 8 sites in United States, Israel
- Volunteers
- 120 people
- Sponsor
- Theranica
Migraine
Metoclopramide for Migraine: A Dose Finding Study
Metoclopramide is an effective intravenous treatment for acute migraine attacks, but we do not know the best dose to administer. This study compares three different doses of metoclorpamide.
- Trial name
- MDFS (NCT00682734)
- Testing
- metoclopramide, Diphenhydramine 25mg
- Where
- United States
- Volunteers
- 349 people
- Sponsor
- Montefiore Medical Center
Migraine With or Without Aura
Eletriptan vs Sumatriptan: A Double-blind, Placebo-controlled, Multiple Migraine Attack Study
A previously published, placebo-controlled, head-to-head comparator study found eletriptan to have superior efficacy to oral sumatriptan 100 mg in treating a single acute migraine attack.
- Trial name
- NCT01986088
- Testing
- Eletriptan 40 mg, Eletriptan 80 mg, Sumatriptan 50 mg
- Volunteers
- 1,008 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Migraine With or Without Aura
Efficacy, Safety, and Tolerability of Oral Eletriptan for Treatment of Acute Migraine
To confirm the efficacy of three dose levels of oral eletriptan relative to placebo in relieving symptoms of acute migraine and to further explore the dose response relationship of eletriptan.
- Trial name
- NCT01978496
- Testing
- Eletriptan 20 mg, Eletriptan 40 mg, Eletriptan 80 mg
- Volunteers
- 1,334 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.